Stem Cell Clinic

Verify the URL – InnovationMap

By Stem Cell Medical Center

Since even the early days of COVID-19's existence, researchers all over the world were rallying to find a cure or potential vaccine which usually take years to make, test, and get approved.

Houston researchers were among this group to put their thinking caps on to come up with solutions to the many problems of the coronavirus. From the testing of existing drugs to tapping into tech to map the disease, here are some research projects that are happening in Houston and are emerging to fight the pandemic.

Baylor College of Medicine has identified a drug that could potentially help heal COVID-19 patients. Photo via bcm.edu

While Baylor College of Medicine has professionals attacking COVID-19 from all angles, one recent discovery at BCM includes a new drug for treating COVID-caused pneumonia.

BCM researchers are looking into Tocilizumab's (TCZ), an immunomodulator drug, effect on patients at Baylor St. Luke's Medical Center and Harris Health System's Ben Taub Hospital.

"The organ most commonly affected by COVID-19 is the lung, causing pneumonia for some patients and leading to difficulty breathing," says Dr. Ivan O. Rosas, chief of the pulmonary, critical care and sleep medicine section at BCM, in a news release.

TCZ, which has been used to successfully treat hyperimmune responses in cancer patients being treated with immunotherapy, targets the immune response to the coronavirus. It isn't expected to get rid of the virus, but hopefully will reduce the "cytokine storm," which is described as "the hyper-immune response triggered by the viral pneumonia" in the release.

The randomized clinical trial is looking to treat 330 participants and estimates completion of enrollment early next month and is sponsored by Genentech, a biotechnology company.

A Texas A&M University researcher is trying to figure out if an existing vaccine has an effect on COVID-19. Screenshot via youtube.com

A researcher from Texas A&M University is working with his colleagues on a short-term response to COVID-19. A vaccine, called BDG, has already been deemed safe and used for treatment for bladder cancer. BDG can work to strengthen the immune system.

"It's not going to prevent people from getting infected," says Dr. Jeffrey D. Cirillo, a Regent's Professor of Microbial Pathogenesis and Immunology at the Texas A&M Health Science Center, in a news release. "This vaccine has the very broad ability to strengthen your immune response. We call it 'trained immunity.'"

A&M leads the study in partnership with the University of Texas MD Anderson Cancer Center and Baylor College of Medicine in Houston, as well as Harvard University's School of Public Health and Cedars Sinai Medical Center in Los Angeles.

Texas A&M Chancellor John Sharp last week set aside $2.5 million from the Chancellor's Research Initiative for the study. This has freed up Cirillo's team's time that was previously being used to apply for grants.

"If there was ever a time to invest in medical research, it is now," Sharp says in the release. "Dr. Cirillo has a head start on a possible coronavirus treatment, and I want to make sure he has what he needs to protect the world from more of the horrible effects of this pandemic."

Currently, the research team is recruiting 1,800 volunteers for the trial that is already underway in College Station and Houston with the potential for expansion in Los Angeles and Boston. Medical professionals interested in the trial can contact Gabriel Neal, MD at gneal@tamu.edu or Jeffrey Cirillo, PhD at jdcirillo@tamu.edu or George Udeani, PharmD DSc at udeani@tamu.edu.

"This could make a huge difference in the next two to three years while the development of a specific vaccine is developed for COVID-19," Cirillo says in the release.

Researchers at Rice University's Center for Research Computing's Spatial Studies Lab have mapped out all cases of COVID-19 across Texas by tapping into public health data. The map, which is accessible at coronavirusintexas.org, also identifies the number of people tested across the state, hospital bed utilization rate, and more.

The project is led by Fars el-Dahdah, director of Rice's Humanities Research Center. El-Dahdah used open source code made available by ESRI and data from the Texas Department of State Health Services and Definitive Healthcare.

"Now that the Texas Division of Emergency Management released its own GIS hub, our dashboard will move away from duplicating information in order to correlate other numbers such as those of available beds and the potential for increasing the number of beds in relation to the location of available COVID providers," el-Dahdah says in a press release.

"We're now adding another layer, which is the number of available nurses," el-Dahdah continues. "Because if this explodes, as a doctor friend recently told me, we could be running out of nurses before running out of beds."

A new compound being developed at Texas Heart Institute could revolutionize the effect of vaccines. Photo via texasheart.org

Molecular technology coming out of the Texas Heart Institute and 7 HIlls Pharma could make vaccines like a potential coronavirus vaccine more effective. The oral integrin activator has been licensed to 7 Hills and is slated to a part of a Phase 1 healthy volunteer study to support solid tumor and infectious disease indications in the fall, according to a press release.

The program is led by Dr. Peter Vanderslice, director of biology at the Molecular Cardiology Research Laboratory at Texas Heart Institute. The compound was first envisioned to improve stem cell therapy for potential use as an immunotherapeutic for certain cancers.

"Our research and clinical colleagues are working diligently every day to advance promising discoveries for at risk patients," says Dr. Darren Woodside, co-inventor and vice president for research at the Texas Heart Institute, in the release. "This platform could be an important therapeutic agent for cardiac and cancer patients as well as older individuals at higher risk for infections."

UH researchers have developed a pliable, thin material that can monitor changes in temperature. Photo via uh.edu

While developed prior to the pandemic, nanotechnology out of the University of Houston could be useful in monitoring COVID patients' temperatures. The material, as described in a paper published by ACS Applied Nano Materials, is made up of carbon nanotubes and can indicate slight body temperature changes. It's thin and pliable, making it ideal for a wearable health tech device.

"Your body can tell you something is wrong before it becomes obvious," says Seamus Curran, a physics professor at the University of Houston and co-author on the paper, in a news release.

Curran's nanotechnology research with fellow researchers Kang-Shyang Liao and Alexander J. Wang, which also has applications in making particle-blocking face masks, began almost 10 years ago.

Read more:
Verify the URL - InnovationMap

Houston banking exec shares tips for keeping online information secure amid COVID-19 threats – InnovationMap

By Stem Cell Medical Center

Since even the early days of COVID-19's existence, researchers all over the world were rallying to find a cure or potential vaccine which usually take years to make, test, and get approved.

Houston researchers were among this group to put their thinking caps on to come up with solutions to the many problems of the coronavirus. From the testing of existing drugs to tapping into tech to map the disease, here are some research projects that are happening in Houston and are emerging to fight the pandemic.

Baylor College of Medicine has identified a drug that could potentially help heal COVID-19 patients. Photo via bcm.edu

While Baylor College of Medicine has professionals attacking COVID-19 from all angles, one recent discovery at BCM includes a new drug for treating COVID-caused pneumonia.

BCM researchers are looking into Tocilizumab's (TCZ), an immunomodulator drug, effect on patients at Baylor St. Luke's Medical Center and Harris Health System's Ben Taub Hospital.

"The organ most commonly affected by COVID-19 is the lung, causing pneumonia for some patients and leading to difficulty breathing," says Dr. Ivan O. Rosas, chief of the pulmonary, critical care and sleep medicine section at BCM, in a news release.

TCZ, which has been used to successfully treat hyperimmune responses in cancer patients being treated with immunotherapy, targets the immune response to the coronavirus. It isn't expected to get rid of the virus, but hopefully will reduce the "cytokine storm," which is described as "the hyper-immune response triggered by the viral pneumonia" in the release.

The randomized clinical trial is looking to treat 330 participants and estimates completion of enrollment early next month and is sponsored by Genentech, a biotechnology company.

A Texas A&M University researcher is trying to figure out if an existing vaccine has an effect on COVID-19. Screenshot via youtube.com

A researcher from Texas A&M University is working with his colleagues on a short-term response to COVID-19. A vaccine, called BDG, has already been deemed safe and used for treatment for bladder cancer. BDG can work to strengthen the immune system.

"It's not going to prevent people from getting infected," says Dr. Jeffrey D. Cirillo, a Regent's Professor of Microbial Pathogenesis and Immunology at the Texas A&M Health Science Center, in a news release. "This vaccine has the very broad ability to strengthen your immune response. We call it 'trained immunity.'"

A&M leads the study in partnership with the University of Texas MD Anderson Cancer Center and Baylor College of Medicine in Houston, as well as Harvard University's School of Public Health and Cedars Sinai Medical Center in Los Angeles.

Texas A&M Chancellor John Sharp last week set aside $2.5 million from the Chancellor's Research Initiative for the study. This has freed up Cirillo's team's time that was previously being used to apply for grants.

"If there was ever a time to invest in medical research, it is now," Sharp says in the release. "Dr. Cirillo has a head start on a possible coronavirus treatment, and I want to make sure he has what he needs to protect the world from more of the horrible effects of this pandemic."

Currently, the research team is recruiting 1,800 volunteers for the trial that is already underway in College Station and Houston with the potential for expansion in Los Angeles and Boston. Medical professionals interested in the trial can contact Gabriel Neal, MD at gneal@tamu.edu or Jeffrey Cirillo, PhD at jdcirillo@tamu.edu or George Udeani, PharmD DSc at udeani@tamu.edu.

"This could make a huge difference in the next two to three years while the development of a specific vaccine is developed for COVID-19," Cirillo says in the release.

Researchers at Rice University's Center for Research Computing's Spatial Studies Lab have mapped out all cases of COVID-19 across Texas by tapping into public health data. The map, which is accessible at coronavirusintexas.org, also identifies the number of people tested across the state, hospital bed utilization rate, and more.

The project is led by Fars el-Dahdah, director of Rice's Humanities Research Center. El-Dahdah used open source code made available by ESRI and data from the Texas Department of State Health Services and Definitive Healthcare.

"Now that the Texas Division of Emergency Management released its own GIS hub, our dashboard will move away from duplicating information in order to correlate other numbers such as those of available beds and the potential for increasing the number of beds in relation to the location of available COVID providers," el-Dahdah says in a press release.

"We're now adding another layer, which is the number of available nurses," el-Dahdah continues. "Because if this explodes, as a doctor friend recently told me, we could be running out of nurses before running out of beds."

A new compound being developed at Texas Heart Institute could revolutionize the effect of vaccines. Photo via texasheart.org

Molecular technology coming out of the Texas Heart Institute and 7 HIlls Pharma could make vaccines like a potential coronavirus vaccine more effective. The oral integrin activator has been licensed to 7 Hills and is slated to a part of a Phase 1 healthy volunteer study to support solid tumor and infectious disease indications in the fall, according to a press release.

The program is led by Dr. Peter Vanderslice, director of biology at the Molecular Cardiology Research Laboratory at Texas Heart Institute. The compound was first envisioned to improve stem cell therapy for potential use as an immunotherapeutic for certain cancers.

"Our research and clinical colleagues are working diligently every day to advance promising discoveries for at risk patients," says Dr. Darren Woodside, co-inventor and vice president for research at the Texas Heart Institute, in the release. "This platform could be an important therapeutic agent for cardiac and cancer patients as well as older individuals at higher risk for infections."

UH researchers have developed a pliable, thin material that can monitor changes in temperature. Photo via uh.edu

While developed prior to the pandemic, nanotechnology out of the University of Houston could be useful in monitoring COVID patients' temperatures. The material, as described in a paper published by ACS Applied Nano Materials, is made up of carbon nanotubes and can indicate slight body temperature changes. It's thin and pliable, making it ideal for a wearable health tech device.

"Your body can tell you something is wrong before it becomes obvious," says Seamus Curran, a physics professor at the University of Houston and co-author on the paper, in a news release.

Curran's nanotechnology research with fellow researchers Kang-Shyang Liao and Alexander J. Wang, which also has applications in making particle-blocking face masks, began almost 10 years ago.

Read the original:
Houston banking exec shares tips for keeping online information secure amid COVID-19 threats - InnovationMap

San Diego biotech firm seeks approval for stem cell research against COVID-19 – CBS News 8

By Stell Cell Research

Personalized Stem Cells Incorporated (PSC) in Poway said the therapy could reduce the most serious complications of the infection in the lungs.

SAN DIEGO A San Diego biotech company is seeking emergency FDA approval for an experimental trial of stem cell therapy for coronavirus patients.

Personalized Stem Cells Incorporated (PSC) in Poway said the therapy could reduce the most serious complications of the infection in the lungs.

PSC CEO, Dr. Bob Harman, said the company is asking to test the treatment on a group of 20 hospitalized COVID-19 patients in the first phase of a clinical trial.

"Stem cell doses will be ready for clinical trial use in May, depending on FDA approval," Harman said.

Harman said they've already scaled up production of stem cells in anticipation of FDA approval.

PSC Medical Director, Dr. Christopher Rogers, stated, "I believe this is the most promising therapy being explored by medical scientists at this time and stem cells may potentially reduce the most serious complications of coronavirus infection."

The FDA has a new program called the Coronavirus Therapeutic Accelerator Program (CTAP) to help speed up the launch of FDA clinical trials for hopeful COVID-19 therapies.

PSC was asked by the White House Coronavirus Task Force to apply to the FDA CTAP program for expedited review of their application.

PSC hopes to rapidly complete the CoronaStem 1 study and then proceed into a larger Phase 2 clinical trial and potentially into FDA compassionate use programs to reach more patients.

More information can be found on the PSC website.

Continue reading here:
San Diego biotech firm seeks approval for stem cell research against COVID-19 - CBS News 8

Amniotic Membrane Market: Locally Available Amniotic Allografts Increasingly Meeting Needs of Patients with Joint Pain – BioSpace

By Stell Cell Research

Transparency Market Research (TMR)has published a new report on theamniotic membrane marketfor the forecast period of2019-2027. According to the report, the global amniotic membrane market was valued at ~US$ 980 Mnin2018and is projected to expand at a CAGR of ~10%from2019to2027.

GlobalAmniotic Membrane Market:Overview

Request for Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=42059

Increase in Research on Stem Cell Biology & Regenerative Medicineto Drive Market

Cryopreserved Amniotic Membrane Products to Dominate Market

Request for Analysis of the COVID19 Impact on Amniotic Membrane Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=42059

Ophthalmology to be Promising Application

Hospitals Account for Major Share of Global Market

North America to Dominate Global Amniotic Membrane Market

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=42059

Global Amniotic Membrane Market: Competitive Landscape

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Transparency Market ResearchState Tower,90 State Street,Suite 700Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email:sales@transparencymarketresearch.comWebsite:https://www.transparencymarketresearch.com

Go here to read the rest:
Amniotic Membrane Market: Locally Available Amniotic Allografts Increasingly Meeting Needs of Patients with Joint Pain - BioSpace

MDimune Signed a Research Collaboration Agreement with Paracelsus Medical University for EV Therapeutics Development – BioSpace

By Stell Cell Research

MDimune Inc., a cell-derived vesicle (CDVs)-based therapeutics company with BioDrone platform technology, announced on April 30th, 2020, the signature of a research collaboration agreement with Paracelsus Medical University (PMU, Salzburg, Austria). PMU will bring their experience to further the companys global development goals.

Those in attendance from PMU were Herbert Resch, Professor and Rector; Michael Nake, Chancellor; Eva Rohde, Professor, Vice Rector and Director of GMP laboratory; and Mario Gimona, Associate Professor and Head of Production GMP. Those in attendance from MDimune were Shin Gyu Bae, Chief Executive Officer; Seung Wook Oh, Chief Scientific Officer; Tae Kee Jeong, Chief Financial Officer; and Hui-Chong Lau, Manager of the CMC team.

The agreement states that PMU will develop a process for producing CDV therapeutics at GMP-compliant scale as well as supply them for the pre-clinical study and the initial phase of human clinical study. PMU has also agreed to establish GMP-grade mesenchymal stem cell banks derived from umbilical cords for MDimune, which will then be used to produce CDVs required for various preclinical and clinical development.

EVs, especially exosomes, have emerged as a novel therapeutic with their roles in intercellular communications. However, the fact that they only naturally occur in minuscule quantities and the difficulties involved in large-scale production have prevented a rapid progress in the commercialization of EVs. MDimune developed BioDrone platform technology to overcome these critical limitations in EV therapeutics. MDimune anticipates that the research collaboration with PMU will accelerate the development of CDVs in therapeutics and the initiation of clinical trials in the US, Europe, and Asia, which will lead to more partnerships in the global market.

MDimune also announced the appointment of Dr. Mario Gimona, a leading exosome expert, as Chief Manufacturing Officer. Dr. Gimona has been heading the stem cell and extracellular vesicle (EV) production unit at PMUs GMP laboratory as well as investigating the clinical potential of multipotent mesenchymal stem cell-derived EVs in the field of regenerative medicine. With his expertise in manufacturing of EV therapeutics, he will be able to help advance the clinical applications of BioDrone platform technology.

We are thrilled to announce a joint research endeavor with Paracelsus Medical University. We are confident that this collaboration will expedite the entry into the clinical phase of development for the company, which will allow us to become a global leader in the field of EV therapeutics and ultimately provide a cure for many patients with devastating diseases around the world, said Bae, CEO of MDimune. Dr. Resch, Rector of PMU also emphasized that combining the individual strengths of MDimune and PMU`s GMP unit will enhance therapy development and ultimately change people`s lives.

About MDimune, Inc.

Founded in 2015, MDimune has been dedicated to changing the world by developing innovative therapeutics. The company has developed BioDrone platform technology, which is a novel technology that uses cell-derived vesicles to achieve highly target-specific drug delivery. The BioDrone platform technology is patented in the US, Europe, China, Japan, and Korea. MDimunes current programs are focused on cancer, COPD and other rare diseases. MDimune is actively pursuing business partnerships with biotech, pharmaceuticals, and hospitals for the potential application of the BioDrone technology in various unmet medical needs. In 2019, MDimune opened its U.S. affiliate BioDrone Therapeutics Inc. in Seattle, WA, to facilitate its global business development.

For more information, visit the company's website at http://mdimune.com/

Contact

Media:

Jinah Han, Ph.D., Consultant, BD (to.jinah.han@gmail.com)

Investor:

Seung Wook Oh, Ph.D. Chief Scientific Officer (swoh@mdimune.com; info@biodroneus.com)

MDimune Inc.

#1003 KOLON Digital Tower-III, 49 Achasan-ro, Seongdong-gu

Seoul 04790 Korea

Tel +82. 2. 2655. 2636

http://www.mdimune.com

Biodrone Therapeutics Inc.

4000 Mason Rd. Suite 300

Seattle, WA 98195

http://www.biodroneus.com

Original post:
MDimune Signed a Research Collaboration Agreement with Paracelsus Medical University for EV Therapeutics Development - BioSpace

Covid-19: How scientists are keeping politics out of the global race for a vaccine – FRANCE 24 English

By Stell Cell Research

As the world races to combat the coronavirus, one nation is notably absent from multinational efforts: the United States.But scientists say that for now, the international research community is working together to do all it can.

Global actors are joining forces on multiple fronts to bring the coronavirus pandemic under control. On April 24, the World Health Organization (WHO) held a virtual conference to launch an international collaboration to accelerate the development and production of the health technologies necessary to do so. The United States did not participate in the conference, which culminated in a joint call for action.

Next Monday, May 4, the European Commission will respond to that call by hosting a global virtual conference to raise money from countries and business foundations to fund the development of tests, treatments and a vaccine for the coronavirus. It has invited governments, business leaders, public figures, philanthropists, artists and citizens to help with its efforts to raise the 7.5 billionit has set as its initial target. Announced partners include France, Germany, the United Kingdom, Norway and Saudi Arabia. It remains unclear if the US will take part.

Under President Donald Trumps America First doctrine, the US has tended to favour unilateral action and eschew cooperation with international organisations. Case in point: On March 14, Trump announced that he was suspending funding to the WHO, which has spearheaded the global response to the pandemic. With an annual input of about $400 million, the US is the biggest contributor to the organisation; the reduction in funds comes at a vital moment.

What all that will mean in the battle against a virus that as global health experts have repeatedly reminded us knows no borders and requires coordinated actionremains to be seen.

Politics a separate sphere from science

On the scientific front, the impact may be minimal. While global cooperation and the sharing of expertise and information is critical, it also happens largely without government involvement and, as of now, continues unimpeded, said Laurent Humeau, chief scientific officer at Inovio Pharmaceuticals.

Humeaus team has relied on the sequencing of the genome provided by China, genetic material from Australia and has cooperated with researchers in South Korea and the UK. Its a community that is moving very fast and we need everyone elses help to get a vaccine, he said. Its absolutely critical for us to have this network of scientists.

The Inovio team is part of the WHOs R & D Blueprint, which pulls together a coalition of experts and allows for the rapid activation of research and development activities during epidemics.

And despite the public distance between the US and the WHO, key health personnel from the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health continue to be part of the global scientific dialogue. For now, the international research community is working together to do all it can. We keep pushing as fast its not as fast as we can run, but as fast as we can fly, Humeau said.

Unless governments issue restrictions such as those the US imposed on stem-cell research politics tends to exist in a sphere separate from science, said Gregory Poland, director of the Mayo Clinics Vaccine Research Group andwho also edits the international journal Vaccine. Youre not working in a political framework at least in the US youre working in a scientific framework, Poland said.

Researchers end up primarily communicating through journals and meetings and, perhaps most importantly in the current crisis, on "preprint servers", where researchers place articles before they have gone through peer review and been published. That has been the primary way that scientists have been communicating with one another, Poland said.

There may even be a silver lining to a little bit of distance between researchers, said Peter Hotez, dean for the National School of Medicine at the Baylor College of Medicine. The US and Europe sometimes have different approaches to vaccine development and how to support vaccine science, and that may not be so bad because it creates additional opportunities for innovation, he said.

Pushed to the bottom?

Poland hopes that this pandemic, unlike the ones that preceded it, will finally have helped people understand how interrelated their nations are. Weve had multiple examples now, that anything that happens anywhere on this globe is maybe, at most, 36 hours away from Europe or North America, he said. Theres where you need a lot of cooperation, for example, on surveillance, on what is happening where, because literally days are lives.

Finding a vaccine is only a first step, warned David Salisbury, associate fellow in the Global Health Programme at Chatham House. The fact that scientists are talking to each other is admirable, because sharing what we are learning about vaccine development is, of course, hugely important," Salisbury said. But that is the beginning of the story Ultimately, weve got to get from developing a vaccine to manufacturing and buying it country by country, and then were into a political world that has left the scientists behind The critical thing is not when do we get the first dose, its when do we get enough.

Manufacturing and distributing a vaccine will be herculean tasks for a disease that potentially affects everyone on the planet, and thats where a new set of potential problems arises. You could imagine a philosophy of America First that might actually prevent vaccines manufactured in the US from leaving the US until everyone [there] had been vaccinated, Salisbury said. Or what if the EU says we will prioritise European customers first? Geopolitics becomes really important in what becomes available when and for whom.

Salisbury said that countries that cant afford to pay market rate also risk getting pushed to the bottom of this great long list of customers. The international community needs to consider carefully how what are certain to be scarce supplies to begin with get distributed.

How do we share a hugely valuable resource equitably? he asked. I dont know that we have a solution yet.

Read the original post:
Covid-19: How scientists are keeping politics out of the global race for a vaccine - FRANCE 24 English

Bone Marrow Transplantation Market to Register CAGR 3.6% Increase in Revenue by 2028 End – Cole of Duty

By Stell Cell Research

In addition to rapid expansion of bone marrow donor registry, increasing commercialization of cellular therapy and tissue engineering, increased survival rate post bone marrow transplant procedures, and easier access to treatment will be some of the most prominent factors driving thebone marrow transplantation market.

According to the latest research by Persistence Market Research, the global bone marrow transplantation market is expected to exceed US$ 12 Bn by the end of 2028. The bone marrow transplantation market is expected to grow at a CAGR of 3.6% through the forecast period 2018-2028.

Report Highlights:

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/4288

Company Profile

North America Will Continue to Lead the Pack in Bone Marrow Transplantation Market

Increasing per-capita healthcare and private insurance expenditure is a major factor that is expected to maintain the high demand for technologically advanced treatment procedures, such as bone marrow transplantation, over the forecast period. Increasing blood cancer cases and geriatric population are among the key factors expected to boost the demand for bone marrow transplantation in North America.

The increasing prevalence of myeloma in the region is leading to an increase in the execution of bone marrow transplantation procedures through the allogeneic method. Companies engaged in stem cell therapies are expanding their product portfolio to offer sound treatment solutions for diseases caused while undergoing the allogeneic transplant method.

The availability of more than 90% unrelated donors and high healthcare expenditure are among the factors driving the overall bone marrow transplantation market in North America at present.

The American Society for Blood and Marrow Transplant reported an increasing prevalence of leukemia and lymphoma in patients aged 65 years and above, and this age group constituted 25-30% of the total number of bone marrow transplantation recipients in 2014.

In 2015, the Senate and House of Representatives of the US reauthorized the Stem Cell Therapeutic and Research Act of 2005, which led to an increase in the US unrelated donors registry to 200,000 donors.

Germany Will Steer Europes Market for Bone Marrow Transplantation

Rise in per capita GDP is expected to improve the healthcare expenditure in countries such as Germany and Spain. Government policymakers are forcing healthcare providers and public payers to disclose the cost charged and reimbursed to maintain price transparency. Healthcare organizations in Germany spend most of their research funding on adult stem cell research.

Furthermore, Germany spends 11.3% of its GDP on healthcare, which is above the global average. This, in turn, has led to the presence of better healthcare facilities and more advanced research findings on various healthcare issues such as bone marrow transplantation.

Among the 680 centers throughout the Europe, 226 (35%) centers are dedicated to autologous bone marrow transplantation in 2014, with most of the transplants intended for non-malignant disorders. These factors are expected to drive the bone marrow transplantation market in Europe.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/4288

APAC Reflects Lucrative Potential for Penetration of Bone Marrow Transplantation Procedures

Rise in the number of bone marrow transplantation centers and expanding donor registry are among the factors expected to reduce the gap between bone marrow transplantation providers and recipients in the Asia Pacific bone marrow transplantation market.

The availability of modern healthcare amenities, along with the presence of several companies engaged in stem cell therapies in China, Australia, and Japan, is expected to be a key factor driving the overall bone marrow transplantation market in Asia Pacific.

After the introduction of alleviating procedures for Peripheral Blood Stem Cell (PBSC) transplant, there has been an increase in the number of allogeneic HSCT procedures using PBSC (64% of the total HSCT) in Australia & New Zealand, which is another factor contributing to the growth of the bone marrow transplantation market in the region.

A survey by the Eastern Mediterranean Blood and Marrow Transplant (EMBMT) Group suggests that non-malignant indications accounted for a 36.5% share of the total bone marrow transplantation activities carried out in the MEA region. Countries such as Dubai and Qatar are undertaking initiatives to develop national bone marrow registries to enhance bone marrow transplantation rates.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/4288

The report offers a comprehensive taxonomy of the bone marrow transplantation market based on the transplantation type, indication, end user, and region.

Continued here:
Bone Marrow Transplantation Market to Register CAGR 3.6% Increase in Revenue by 2028 End - Cole of Duty

(COVID-19 UPDATE)Mesenchymal Stem Cells MARKET TO WITNESS INCREASED REVENUE GROWTH OWING TO HEIGHTENED PRODUCT INNOVATIONS IN THE COVID-19 PANDEMIC -…

By Stell Cell Research

Mesenchymal Stem Cells Market Latest Research PDF Of COVID 19 Impact Study By eSherpa Market Reports | Top players Genlantis, Inc., Stem cell technologies Inc., Cytori Therapeutics Inc., BrainStorm Cell Therapeutics., Cyagen Biosciences Inc., Aastrom Biosciences, Axol Bioscience Ltd., Advanced Cell Technology Incorporated, EMD Millipore Corporation, Stemedica Cell Technologies, Inc., R&D Systems, Inc., ScienCell Research Laboratories., Cell Applications, Inc., Celprogen, Inc.

Mesenchymal Stem Cells Market Report is exclusive and talks in detail about the current market situations. Also, about the overall market journey in the previous five years along with the prophecy made by the experts in the industry. However, the report also provides the necessary SWOT analysis as its one of the main elements.

In revenue terms, in the worldwide market, the Mesenchymal Stem Cells Market is forecasted to generate the XX% CAGR. the market share, sales, and revenues are shared in this report for the XX industry, from the worldwide market. According to the forecast the worldwide market for the Mesenchymal Stem Cells industry will reach from $XX billion in 2020 to $XX billion in 2027. The market will show the XX% profit in the Mesenchymal Stem Cells industry in the next 7 years.

Get Free Sample PDF Copy (including COVID19 Impact Analysis, full TOC, Tables, and Figures) of Mesenchymal Stem Cells Market Report @ https://www.esherpamarketreports.com/request-sample/es-412584/

Key Businesses Segmentation of Mesenchymal Stem Cells Market:

Global Mesenchymal Stem Cells Market Segment by Type, covers

Global Mesenchymal Stem Cells Market Segment by Applications, can be divided into

The Mesenchymal Stem Cells Market Report Can Answer The Following Questions:

Enquire before purchasing this report @ https://www.esherpamarketreports.com/pre-order-enquiry/es-412584

Table of Contents

1 Mesenchymal Stem Cells Market Overview1.1 Product Overview and Scope of Mesenchymal Stem Cells1.2 Mesenchymal Stem Cells Segment by Type1.2.1 Global Mesenchymal Stem Cells Production and CAGR (%) Comparison by Type (2015-2027)1.3 Global Mesenchymal Stem Cells Segment by Application1.3.1 Mesenchymal Stem Cells Consumption (Sales) Comparison by Application (2015-2027)1.4 Global Mesenchymal Stem Cells Market by Region (2015-2027)1.4.1 Global Mesenchymal Stem Cells Market Size (Value) and CAGR (%) Comparison by Region (2015-2027)1.4.2 United States Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.3 Europe Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.3.1 Germany Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.3.2 UK Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.3.3 France Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.3.4 Italy Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.3.5 Spain Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.3.6 Russia Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.3.7 Poland Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.4 China Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.5 Japan Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.6 India Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.7 Southeast Asia Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.7.1 Malaysia Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.7.2 Singapore Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.7.3 Philippines Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.7.4 Indonesia Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.7.5 Thailand Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.7.6 Vietnam Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.8 Central and South America Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.8.1 Brazil Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.8.2 Mexico Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.8.3 Colombia Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.9 Middle East and Africa Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.9.1 Saudi Arabia Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.9.2 United Arab Emirates Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.9.3 Turkey Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.9.4 Egypt Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.9.5 South Africa Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.4.9.6 Nigeria Mesenchymal Stem Cells Market Status and Prospect (2015-2027)1.5 Global Market Size (Value) of Mesenchymal Stem Cells (2015-2027)1.5.1 Global Mesenchymal Stem Cells Revenue Status and Outlook (2015-2027)1.5.2 Global Mesenchymal Stem Cells Production Status and Outlook (2015-2027)2 Global Mesenchymal Stem Cells Market Landscape by Player2.1 Global Mesenchymal Stem Cells Production and Share by Player (2015-2020)2.2 Global Mesenchymal Stem Cells Revenue and Market Share by Player (2015-2020)2.3 Global Mesenchymal Stem Cells Average Price by Player (2015-2020)2.4 Mesenchymal Stem Cells Manufacturing Base Distribution, Sales Area and Product Type by Player2.5 Mesenchymal Stem Cells Market Competitive Situation and Trends2.5.1 Mesenchymal Stem Cells Market Concentration Rate2.5.2 Mesenchymal Stem Cells Market Share of Top 3 and Top 6 Players2.5.3 Mergers & Acquisitions, Expansion3 Players Profiles4 Global Mesenchymal Stem Cells Production, Revenue (Value), Price Trend by Type

. And More

Click Here For Detailed Table Of Contents

Reasons To Buy:

Purchase this Report with Full Access @ https://www.esherpamarketreports.com/purchase/es-412584/

Contact Us:

Name: Jason George

Email: sales@esherpamarketreports.com

Call :USA: +1 408 757 0510

Organization: eSherpa Market Reports

About Us:

eSherpa Market Reports is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segment.

Read the original here:
(COVID-19 UPDATE)Mesenchymal Stem Cells MARKET TO WITNESS INCREASED REVENUE GROWTH OWING TO HEIGHTENED PRODUCT INNOVATIONS IN THE COVID-19 PANDEMIC -...

Placental Stem Cells (PSCS) Market is Prospering With Healthy CAGR in 2020. Leading Players are Cryo-Cell International, Inc., ESPERITE NV, LifeCell…

By Stell Cell Research

This Placental Stem Cells (PSCS) industry report provides comprehensive analysis as follows Market segments and sub-segments, Market size, Market trends and flow, Major Manufacturers Production and Sales Market Comparison Analysis, Drivers and Opportunities, Competitive scene, Product Specification and Major Types Analysis, Supply and demand, Regional Production Market Analysis, Regional Market Performance and Market Share. The Placental Stem Cells (PSCS) market research report covers effectiveness and summary of the marketing research. These results can be employed to make improvements in the business. The report helps to save a large amount of time and money that may get spend on marketing.

Get ExclusiveSample Copy of This Report Herehttps://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-placental-stem-cells-pscs-market

Placentalstem cells(PSCS) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to growing at a CAGR of 10.25% in the above-mentioned forecast period. Increasing awareness regarding the benefits associates with the preservation of placental derived stem cells will boost the growth of the market.

The major players covered in theplacental stem cells (PSCS) marketreport areCBR Systems, Inc, Cordlife India, Cryo-Cell International, Inc., ESPERITE N.V., LifeCell International Pvt. Ltd., StemCyte India Therapeutics Pvt. Ltd, PerkinElmer Inc, Global Cord Blood Corporation., Smart Cells International Ltd., Vita 34, among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately.DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Market Analysis and Insights of Global Placental Stem Cells (PSCS) Market

Adoption of advances and novel technologies that will lead to the storage and preservation of stem cells, technological advancement in the field of biotechnology, introduction of hematopoietic stem cell transplantation system and growing number of diseases which will helps in accelerating the growth of the placental stem cells (PSCS) market in the forecast period of 2020-2027. Surging number of applications from emerging economies along with rising awareness among the people will further boost many opportunities that will led to the growth of the placental stem cells (PSCS) market in the above mentioned forecast period.

Increasing operation costs along with stringent regulatory framework will likely to hamper the growth of the placental stem cells (PSCS) market in the above mentioned forecast period. Social and ethical issues will be the biggest challenge in the growth of the market.

Thisplacental stem cells(PSCS) market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on placental stem cells (PSCS) market contactData Bridge Market Researchfor anAnalyst Brief, our team will help you take an informed market decision to achieve market growth.

Read Complete Details with TOC Herehttps://www.databridgemarketresearch.com/toc/?dbmr=global-placental-stem-cells-pscs-market

Global Placental Stem Cells (PSCS) Market Scope and Market Size

Placental stemcells(PSCS) market is segmented on the basis of service type and application. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Placental Stem Cells (PSCS) Market Country Level Analysis

Placental stemcells(PSCS) market is analysed and market size insights and trends are provided by country, service type and application as referenced above.

The countries covered in the placental stem cells (PSCS) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the bone marrow-derived stem cells (BMSCS) market due to the increasing stem cell procedure along with preferences of private stem cell banking over public and surging network of stem cell banking services.

The country section of the placental stem cells (PSCS) market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Placental stem cells (PSCS) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipments, installed base of different kind of products for placental stem cells (PSCS) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the placental stem cells (PSCS) market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Placental Stem Cells (PSCS) Market Share Analysis

Placental stem cells (PSCS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to placental stem cells (PSCS) market.

To Get This Report at an Attractive Cost, Click Herehttps://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-placental-stem-cells-pscs-market

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475Mail:Corporatesales@databridgemarketresearch.com

Read more from the original source:
Placental Stem Cells (PSCS) Market is Prospering With Healthy CAGR in 2020. Leading Players are Cryo-Cell International, Inc., ESPERITE NV, LifeCell...

Asia-Pacific Animal Stem Cell Therapy Market by Trends, Key Players, Driver, Segmentation, Forecast to 2025 – Latest Herald

By Stell Cell Research

Hongchun Research latest addition on Asia-Pacific Animal Stem Cell Therapy market is a research that features comprehensive outlook pertaining to market valuations, market share, profit estimations, and the geographical spectrum of this business. The report precisely describes key obstacles and opportunities for growth, while drawing out competitive standing of market majors, including their portfolio and growth strategies.

Get PDF Sample Copy on Global Animal Stem Cell Therapy Market @https://hongchunresearch.com/request-a-sample/1025

According to the Global Animal Stem Cell Therapy Market Report, the Animal Stem Cell Therapy Market is expected to witness steady to high growth rate owing to the increased demands from various industries, as well as the regions which are developing at a quick pace. The buying capability and rise in disposable incomes is also a major factor here affecting the Global Animal Stem Cell Therapy Market positively. The Global Animal Stem Cell Therapy Market Report covers the rest of the current trends / opportunities / challenges in substantial detail.

Market Segmentation is one of the key factors of any Market Report. The Global Animal Stem Cell Therapy Market report ensures that the customers receive detailed information of all the Animal Stem Cell Therapy market segments and sub-segments, and hence are covered in a much elucidated fashion. The Global Animal Stem Cell Therapy Market is segmented into various types such as by product, application, end users, and regions.

The global Intelligent Intravenous Infusion Pumps market report is a comprehensive study that encompasses top manufacturers, prospective market share, revenue, purchaser volume with respect to dealing volume and global segmentation for the Intelligent Intravenous Infusion Pumps industry. The report further includes market classification and definitions, product and industry overview, manufacturing specifications and cost structure, included raw materials and so on.

In addition to the vast definitive data, the report also sheds light on the past behavior of the market and an upcoming growth graph that is expected to venture in an upwards trajectory despite market fluctuations and trends.

Access Research Report on Global Animal Stem Cell Therapy Market @ https://hongchunresearch.com/report/asia-pacific-animal-stem-cell-therapy-market-1025

Market Segmentation:The Intelligent Intravenous Infusion Pumps report follows an accumulated research methodology that is based on years of experience combined with structured data points acquired from proprietary sources. These methods function with thorough research and analysis split between primary and secondary research combined with an in-house data wrangling process. In general, the data points are gathered from a variety of sources such as vendor projections, product list, research papers and a detailed list of manufacturers. The analysis is than derived into quantitative market values such as qualitative and quantitative qualities, market forecast models, market segmentations and business models that revolve around the Intelligent Intravenous Infusion Pumps industry.

Moreover, the Intelligent Intravenous Infusion Pumps market report clarifies the market segmentation based on various parameters and attributes that can be classified on geographical region, product types and market applications.

The reports shows the different typesvolume and Value in different applications. The major Intelligent Intravenous Infusion Pumps Market (The Northeast, The Midwest, The Southwest, The Southeast, The West) is analyzed, data including: market size, import and export, sale segment market by product type and applications.

Market Analysis by PlayersBDAbbott LaboratoriesSmiths MedicalB. BraunHospiraBaxterMoogCareFusionMindrayZollIradimedTeleflexMedlineZyno MedicalMaxim

Market Analysis by Regions:The NortheastThe MidwestThe SouthwestThe SoutheastThe West

Market Analysis by Types:Constant Volume Control TypeSyringe Injection TypeOthers

Market Analysis by Applications:HospitalClinicOthers

The report also focuses on developing market trends, preferred market channels and market drivers & restraints to name a few.

Get More Information on Global Animal Stem Cell Therapy Industry @ https://hongchunresearch.com/enquiry-before-buying/1025

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

Original post:
Asia-Pacific Animal Stem Cell Therapy Market by Trends, Key Players, Driver, Segmentation, Forecast to 2025 - Latest Herald

→←